BioNTech lifts 2021 COVID-19 vaccine output target to 2 bln doses
Pfizer's partner BioNTech boosted the 2021 delivery target for their COVID-19 vaccine to 2 billion doses, up from 1.3 billion previously, as they bring new production lines on stream and as more doses can be extracted per vial.
Pfizer's partner BioNTech boosted the 2021 delivery target for their COVID-19 vaccine to 2 billion doses, up from 1.3 billion previously, as they bring new production lines on stream and as more doses can be extracted per vial. Special syringes known as low dead space syringes were instrumental in the increase, which would result in 1 billion people getting the designated two-dose regimen, BioNTech said in a presentation posted on Monday.
The syringes allow the extraction of six doses from a standard vial, instead of the usual five, by avoiding unused liquid left in a syringe. "We now believe that we can potentially deliver approximately 2 billion doses in total by the end of 2021, which incorporates the updated six-dose label," BioNTech said.
A new site in Marburg, Germany, acquired from Novartis in September, would boost annual capacity by up to 750 million doses when it becomes operational by end-February, it added. Additional capacity by contractors, who supply ingredients and fill the finished substance into vials, had also helped to lift the target.
The Biotech firm added on its slides that 32.9 million doses had been shipped as per Sunday. A spokeswoman said that 50 million doses had been produced at the end of 2020, as previously planned, but that deliveries had been held until specific orders are placed to avoid excess storage time. (Additional reporting by Thomas Seythal and Patricia Weiss, editing by Louise Heavens Editing by Riham Alkousaa)
(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)
ALSO READ
Health News Roundup: GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology; Gilead posts quarterly loss, revenue rises 5% and more
Vice President Jagdeep Dhankhar's Visit to Bharat Biotech Facility in Hyderabad
The future belongs to Bharat - VP Dhankhar says at Bharat Biotech in Hyderabad
GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology
GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology